Kisspeptin research: the mechanism, the human numbers, and what they actually measured.

Before the details

Kisspeptin research has a tidy spine. It opens with human genetics — people missing a working GPR54 receptor never finish puberty, which is how scientists learned this signal is essential. It moves to the cellular machinery — how kisspeptin makes a GnRH neuron fire. Then come the human studies: give kisspeptin and watch LH rise, in healthy men, in women who have lost their cycles, and in IVF. The headline findings are real and repeatable: LH climbs within minutes, cycles can be coaxed back, and a kisspeptin trigger matured eggs in IVF with no severe over-stimulation. The honest caveat runs alongside all of it — give the signal continuously and it fades (tachyphylaxis), so how it is given matters as much as how much. Below, each finding gets its own section, with the source attached.

The genetics that proved the switch

The foundation is human, not animal. Loss-of-function mutations in GPR54 (KISS1R) cause autosomal-recessive idiopathic hypogonadotropic hypogonadism — absent or incomplete puberty with low LH and FSH — and Gpr54-knockout mice reproduced the phenotype, together establishing kisspeptin–GPR54 signaling as essential for reproductive maturation ^[1]. This is why kisspeptin is called a gatekeeper of puberty: remove the receptor and the axis never starts.

How kisspeptin fires a GnRH neuron

At the cellular level the mechanism is now well drawn. Kisspeptin (applied at 100 nM) depolarized GnRH neurons by 6 ± 1 mV and raised their firing rate by 87 ± 4% in roughly 75% of adult GnRH neurons tested ^[2]. The response runs through a phospholipase-C / IP3 / intracellular-calcium cascade (the cell's internal-signal relay) that closes potassium channels and opens non-selective cation channels — the ionic events that depolarize the neuron and drive pulsatile GnRH release ^[2]. The receptor, KISS1R, is a Gq/11-coupled GPCR; the KNDy neurons of the arcuate nucleus are thought to be the pulse generator that paces the rhythm ^[2].

Kisspeptin in men: LH, pulse frequency and testosterone

In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at a 1 µg/kg bolus, lifting LH from 4.1 to 12.4 IU/L at 30 minutes; continuous infusion at 1.5 µg/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/h, while a higher 4 µg/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L ^[3]. Kisspeptin-54 showed the same direction in men: a 4 pmol/kg/min IV infusion for 90 minutes raised mean 90-minute LH to 10.8 ± 1.5 versus 4.2 ± 0.5 U/L on saline, with smaller rises in FSH and testosterone (LH > FSH > testosterone) ^[8]. A head-to-head comparison found IV kisspeptin-10 and kisspeptin-54 gave comparable gonadotropin responses at matched infusion rates ^[9].

Kisspeptin fertility research: restoring cycles and triggering IVF

The fertility work is where kisspeptin research is furthest along. In women with hypothalamic amenorrhea — periods lost to stress, low weight or heavy exercise — continuous IV kisspeptin-54 (0.01–1.00 nmol/kg/h) restored pulsatile LH secretion: LH pulses rose from 1.6 to 5.0 per 8 hours (about threefold) and pulse secretory mass rose roughly sixfold versus vehicle, though the highest dose produced tachyphylaxis over the infusion ^[4].

In IVF, kisspeptin offered a safer trigger. A Phase 2 randomized trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) used subcutaneous kisspeptin-54 (3.2–12.8 nmol/kg) to trigger oocyte maturation in 95% of women, with no case of moderate, severe or critical OHSS; the highest live-birth rate (62%) followed the 9.6 nmol/kg dose ^[5]. Supporting the same axis, a study of 50 unexplained-infertility women undergoing ICSI found follicular-fluid kisspeptin rose through stimulation and correlated positively with oocyte maturity and endometrial thickness ^[13].

The newest route, and the field map

In 2025, kisspeptin research crossed a practical threshold: intranasal kisspeptin-54 (primary dose 12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L) and women with hypothalamic amenorrhea (+4.4 IU/L) without adverse events, and the nasal-spray formulation stayed stable up to 60 days at 4 °C — the first clinical demonstration of an effective non-invasive route ^[6]. Zooming out, a 2025 systematic review mapped 29 interventional trials spanning amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation, and noted comparatively few side effects — while confirming that no kisspeptin product is regulatory-approved ^[7]. The same KNDy circuitry sits at the center of functional hypothalamic amenorrhea, where stress, disordered eating and low body weight suppress GnRH pulsatility and lower LH and estradiol ^[14], and kisspeptin is among the markers proposed to help distinguish that condition from polycystic ovary syndrome, pending further study ^[15].